The C-terminal tetrapeptide amide of gastrin, the shortest sequence of this gastrointestinal hormone
capable of exhibiting all the biological properties even though at reduced potency, and the related heptapeptide
amide were covalently linked to mono-(6-succinylamino-6-deoxy)-β-cyclodextrin to analyze the effect of the
bulky cyclic carbohydrate moiety on recognition of the peptides by the G-protein-coupled CCK−B/gastrin
receptor and on their signal transduction potencies. With the four-carbon succinyl spacer and particularly
with the additional tripeptide spacer in the heptapeptide/β-cyclodextrin conjugate, full recognition by the receptor
was obtained with binding affinities identical to those of the unconjugated tetrapeptide and with a potency
comparable to that of full agonists. Docking of this conjugate onto a structure of the human CCK−B receptor
derived by homology modeling indicates sufficient free space of the peptide moiety for intermolecular interaction
at the putative gastrin binding site, whereby additional interactions of the cyclodextrin with the receptor surface
apparently suffice for stabilizing the complex and thus for triggering the full hormonal message. The host/guest complexation of the peptide moiety by the β-cyclodextrin which seems to occur at least in the case of
the tetrapeptide conjugate does not suffice in its strength for competing with the receptor recognition. However,
multiple presentation of the tetragastrin by its covalent linkage to the heptakis-(6-succinylamino-6-deoxy)-β-cyclodextrin leads to peptide/peptide and/or peptide/cyclodextrin collapses with strong interferences in the
receptor recognition process. Retention of full agonism by suitably designed monoconjugates of bioactive
peptides with cyclodextrins suggests a highly promising approach for targeting host/guest complexed or
covalently bound cytotoxic drugs to specific tumor cells for receptor-mediated internalization.